PepsiCo doesn't 'see any impact' from weight loss drugs: CFO

In This Article:

PepsiCo (PEP) reported third quarter results that topped analyst estimates on both the top and bottom lines. The food and beverage company also raised its full-year earnings outlook. There has been a lot of concern about how the popularity of weight loss drugs such as Ozempic could hurt companies like PepsiCo. PepsiCo CFO Hugh Johnston tells Yahoo Finance Live the company "can't detect any impact on our numbers right now. We just don't see any impact at all," though he cautions "this is early days in terms of these drugs," pointing to questions such as rate of adoption. Johnston also points to how the company has been trying to stay ahead of the consumer and developing products with zero sugar and smaller portion sizes, for example.

When it comes to the outlook, Johnston says "we plan the consumer conservatively... and more often than not the consumer surprises us on the upside. So, we put ourselves in a good position to meet or beat our guidance." On pricing, Johnston says he thinks inflation will remain "a little elevated" compared to pre-pandemic levels and that the company has been pricing "in-line with inflation." Given where inflation is, pricing could be "a little bit elevated relative to history," Johnston says.

For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Video Transcript

BRAD SMITH: You know, first and foremost, a lot of investors, a lot of viewers here as well might be looking through some of the commentary that was provided during this quarter afterwards and they saw this note about normalization, saying that there are coming years with category growth and normalizing. Is there an analogous period that they can think back to to know what that growth and normalization of it may look like?

HUGH JOHNSTON: Yeah, good morning. Happy to be with you guys again. Well, I think the best way to think about what we meant by that comment was, post this sort of very high inflation period, as inflation comes down, now, it's not going to be all the way back to pre-pandemic levels of 2% or 3% in our business, so a little bit elevated versus that, but certainly reduced from what it was in the past. The indication we were giving was a lead into the guide that we've provided for '24, which is the upper end of our long term guidance on revenue, so that would be 5% to 6% revenue growth.

Our long term guide is 4% to 6%, and then the upper end of our EPS guide, which would be 8% to 9% at the upper end. So that was really the intention of that normalization comment was to talk about the fact that revenue growth numbers, which have been in the double digits for now several years, are likely to come back into that mid to high single digit range.